Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.
Joseph J. Wolk net worth and biography

Joseph Wolk Biography and Net Worth

Exec. VP & CFO of Johnson & Johnson

Joseph J. Wolk (Joe) is the Executive Vice President and Chief Financial Officer for Johnson & Johnson. Joe serves as a member of the company’s Executive Committee, plays a strategic role in the overall management of the organization and leads the development and execution of the business’ global long-term financial strategy. Additionally, as a financial steward of Johnson & Johnson, Joe’s scope of responsibilities include driving competitive and profitable growth, generating sustainable cash flow, allocating capital to maximize value creation and managing risk across the entire enterprise.

Joe leads the worldwide Finance and Global Services organizations, which comprise approximately 9,000 colleagues around the globe. He assumed the role of Chief Financial Officer in July 2018 and has been with Johnson & Johnson for 23 years.

Prior to assuming his current responsibilities, Joe was the Vice President of Investor Relations for Johnson & Johnson. In this role, he developed a winning strategy for building strong relationships with the investment community and disseminating Johnson & Johnson’s value creation narrative to all external financial stakeholders. During Joe’s tenure in this role, the Investor Relations function was regularly recognized by Institutional Investor as one of the best teams in the industry.

Prior to Investor Relations, Joe held a variety of senior leadership roles in several segments and functions across the company, where he achieved superior results. He served as Vice President of Finance for the Pharmaceuticals Group, Vice President of Finance for the Medical Devices Global Supply Chain and Chief Financial Officer of the North America Pharmaceuticals Group.

Joe is an accomplished, Credo-based leader, and is passionate about talent development, driving innovation and community service. He is the executive sponsor of Johnson & Johnson’s Impact Venture Fund, an “impact investment” fund that provides funding to entrepreneurs and their start-up companies or social enterprises to address healthcare challenges impacting people around the world. He is also the executive sponsor of the Veterans Leadership Council and a champion of the Finance Leadership Development Program. Additionally, he is a member of the Stanford Medicine Board of Fellows, the CNBC Global CFO Council and the Wall Street Journal CFO Network.

Joe holds a Bachelor of Science degree in Finance from St. Joseph’s University, where he currently serves on the Haub School of Business Board of Visitors, and a Juris Doctor degree from Temple University School of Law. He is also a Certified Public Accountant (CPA).

How old is Joseph J. Wolk?

Wolk is currently 55 years old. There are 6 older executives and no younger executives at Johnson & Johnson. The oldest executive at Johnson & Johnson is Mr. Michael H. Ullmann, Exec. VP & Gen. Counsel, who is 63 years old. Learn More on Joseph J. Wolk's age.

What is Joseph J. Wolk's salary?

As the Exec. VP & CFO of Johnson & Johnson, Wolk earned a total compensation package of $10,953,615.00 in 2021. Wolk earned a salary of $938,077.00, stock awards of $4,877,538.00, options awards of $1,688,997.00, non-equity compensation of $1,560,863.00, and other compensation of $78,243.00. Learn More on Joseph J. Wolk's salary.

How do I contact Joseph J. Wolk?

The corporate mailing address for Wolk and other Johnson & Johnson executives is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. Johnson & Johnson can also be reached via phone at (732) 524-0400. Learn More on Joseph J. Wolk's contact information.

Has Joseph J. Wolk been buying or selling shares of Johnson & Johnson?

Joseph J. Wolk has not been actively trading shares of Johnson & Johnson during the past quarter. Learn More on Joseph J. Wolk's trading history.

Who are Johnson & Johnson's active insiders?

Johnson & Johnson's insider roster includes Dominic Caruso (VP), Robert Decker (CAO), Joaquin Duato (CEO & Director ), Peter Fasolo (VP), Alex Gorsky (CEO), William Hait (Insider), Ronald Kapusta (CAO), Ashley McEvoy (EVP), Thibaut Mongon (VP), William Perez (Director), Michael Sneed (COO), Paulus Stoffels (VP), Kathryn Wengel (EVP), and Joseph Wolk (Exec. VP & CFO ). Learn More on Johnson & Johnson's active insiders.

Are insiders buying or selling shares of Johnson & Johnson?

During the last year, insiders at the sold shares 5 times. They sold a total of 106,842 shares worth more than $18,885,128.67. The most recent insider tranaction occured on June, 10th when EVP Kathryn E Wengel sold 40,000 shares worth more than $6,920,000.00. Insiders at Johnson & Johnson own 0.4 % of the company. Learn More about insider trades at Johnson & Johnson.

Information on this page was last updated on 6/10/2022.

Joseph J. Wolk Insider Trading History at Johnson & Johnson

See Full Table

Joseph J. Wolk Buying and Selling Activity at Johnson & Johnson

This chart shows Mr. Joseph J. Wolk CPA's buying and selling at Johnson & Johnson by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Johnson & Johnson Company Overview

Johnson & Johnson logo
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Read More

Today's Range

Now: $163.36
Low: $163.32
High: $165.74

50 Day Range

MA: $167.13
Low: $161.33
High: $174.59

2 Week Range

Now: $163.36
Low: $155.72
High: $186.69


8,961,384 shs

Average Volume

7,531,909 shs

Market Capitalization

$429.50 billion

P/E Ratio


Dividend Yield



Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.